Compass Therapeutics, Inc. CMPX R2KR3KPHARMA
Company Overview
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | -75.45% |
| 6 Months: | -84.87% |
| 3 Months: | -63.41% |
| 1 Month: | -32.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)21.53 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 88.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 22 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CMPX Compass Therapeutics, Inc. R2KR3KPHARMA | 0.76 | -1.95 | $136.87M | 0.00% | -35.42% | -56.66% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | - | 850.00K | 0 | - | 0 | 0 | - | - |
| Operating Income | -7.89K | -7.79K | -9.27K | - | -8.67M | -8.38M | -10.24K | -5.83M | -5.07M | -8.96M | -7.34M | -55.69M | -5.85M | -7.18M | -8.99M | -12.60M | -9.71M | -13.34M | -11.93M | -12.77M | -15.04M | -12.24M | -17.97M | -21.07M | -15.82M | -20.30M | -26.98M |
| Net Income | -8.47K | -8.56K | -10.14K | -10.77M | -8.81M | -8.55M | -11.68K | -6.40M | -5.56M | -9.15M | -7.42M | -55.80M | -5.97M | -7.16M | -8.49M | -11.97M | -7.84M | -11.28M | -9.96M | -10.79M | -13.08M | -10.48M | -16.63M | -19.88M | -14.26M | -18.32M | -25.15M |
| R&D Expense | - | - | - | - | 5.39M | 5.98M | - | 3.57M | 2.98M | 3.67M | 4.70M | - | - | - | - | - | - | - | - | 9.52M | 11.17M | 8.61M | 13.05M | 16.41M | 12.83M | 13.39M | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2019 | Dec 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 850.00K | 0 |
| Operating Income | -32.76K | -34.05M | -32.10K | -27.81M | -81.88M | -41.66M | -50.36M | -56.62M | -72.84M |
| Net Income | -36.04K | -34.74M | -37.48K | -29.50M | -82.18M | -39.23M | -42.49M | -49.38M | -66.49M |
| R&D Expense | - | 22.45M | - | 14.90M | - | - | 38.12M | 42.34M | 55.97M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2018 | Dec 2018 | Mar 2019 | Dec 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 25 | - | 4.87K | 30.38M | 3.75K | 51.91M | 153.76M | 199.65M | 156.88M | 140.40M | 219.59M |
| Total Equity | -34.55K | -84.77M | -70.59K | 11.27M | -108.07K | 39.95M | 140.08M | 181.64M | 148.54M | 125.23M | 196.79M |
| Cash & Equivalents | - | - | 4.87K | 25.30M | 3.75K | 47.08M | 144.51M | 34.95M | 24.23M | 43.48M | 30.64M |
| Long Term Debt | - | - | - | 9.29M | - | 1.87M | 0 | - | - | - | - |
| Total Liabilities | 34.58K | - | 75.45K | 19.11M | 111.82K | 11.97M | 13.68M | 18.01M | 8.34M | 15.17M | 22.80M |
| Current Liabilities | 34.58K | - | 75.45K | 9.82M | 111.82K | 10.10M | 10.63M | 16.17M | 7.80M | 8.87M | 13.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2019 | Dec 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.76K | -31.74M | -32.11K | -26.80M | -19.67M | -34.12M | -40.62M | -44.85M | -49.14M |
| Investing Cash Flow | - | -466.00K | - | 38.00K | -1.77M | -151.20M | 26.96M | 46.77M | -93.31M |
| Financing Cash Flow | 37.62K | - | 30.98K | 48.54M | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Capital Expenditure | - | -466.00K | - | -106.00K | -1.57M | -212.00K | -30.00K | -44.00K | -25.00K |
| Free Cash Flow | - | -32.21M | - | -26.91M | -21.23M | -34.34M | -40.65M | -44.90M | -49.17M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Dec 2019 | Mar 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -6,661.8% | - |
| Net Margin % | - | - | - | - | - | - | - | -5,808.8% | - |
| ROE % | 51.1% | -308.4% | 34.7% | -73.9% | -58.7% | -21.6% | -28.6% | -39.4% | -33.8% |
| ROCE % | 46.4% | -165.6% | 29.7% | -66.5% | -57.2% | -22.7% | -33.8% | -43.1% | -35.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Tang Capital Management, LLC | 34.52% | 17.99M | $17.86M |
| 2 | Orbimed Advisors LLC. | 29.20% | 15.22M | $15.11M |
| 3 | Montanova Capital LLC | 27.05% | 14.10M | $14.00M |
| 4 | Blackrock Inc. | 21.64% | 11.28M | $11.20M |
| 5 | State Street Corporation | 19.10% | 9.95M | $9.88M |
| 6 | Enavate Sciences Gp, LLC | 14.94% | 7.79M | $7.73M |
| 7 | Vivo Capital, LLC | 14.88% | 7.76M | $7.70M |
| 8 | Vanguard Capital Management LLC | 11.74% | 6.12M | $6.08M |
| 9 | Palo Alto Investors Lp | 11.19% | 5.83M | $5.79M |
| 10 | Millennium Management Llc | 9.04% | 4.71M | $4.68M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CMPX
Compass Therapeutics (CMPX) Stock Fair Value Falls After Tovecimig Regulatory Concerns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNbU1GNGJPM3VrLW5EWndiN0RwRU15OGNDSnRONlk1Z3h3R1JLYnlIRllfcTJBSGJwVF9tcUxkeHp1OElhdzJUTnlHMmtZYWxVUjZkOERaR21tb1JvTmw3cmQtRzFFMS1JSjhoWElldFgzQmZmS2c0MUNNa0JSSVNQeElraGMxX08tTW9VN0…
Compass Therapeutics CAO Neil Lerner buys $2,849 in CMPX shares - Investing.com
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOb2Rfd0w4b3E2SWQ4UXY0dTVmWmNkemIwcjdwN2Z6d3pKalVoMzJBdnNFM2pxam45WTdZSXRhZE9sdDNxbmlaOEFJRTE0ZXRwX29lcGhsakIyTTRUbGxGU0xFY2kzVkZ0UXZBRnVGOVNxaUxLOE5fSzh1bW9lUTE0aG1iWDMyQU5XR0JSbk…
Why Did Compass Therapeutics Stock Plunge Today? - Compass Therapeutics (NASDAQ:CMPX) - Benzinga
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNYlBGLXZXZTM3d3lMRlpFTWlsYU5OSFFlel82MlRVSU1MUmxQZ1RteE5TNzJLN1FaUUFOUUZTd1dfdXZzSU42WnF3eDJONFR6LXgtbDVOc3g1WHh3WmowZms5aDRJd3haTGZINGVXc1JHUlFnQmIyTVVCWGhSanVUUHZVOEZfZG45U2IwZn…
CMPX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9YYV9Pak9LbVVsTFByN3h3UWJhOEpBM0RaUG1CZ1QtbHZKZzlYZ3ZzeXdxckxTa05FTjQ1N1hRU3ptZkZYUFR6bUVxYXg0cVVVdVZvZ0NGaG0wSXlUVzVFZGYtX3BIdm5wc0N0TU1CRnFaaWhPaGttOVpR?oc=5" target="_blank">CMP…
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity (NASDAQ:CMPX) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQMG1yay1uMmk3bkg4TkRhcHUzSTF0dk92bzg2LTRnWExNR1FrTVVDdTdlZTUwVGM2ZlVEa2dxanBiUnAxV3VNMkJmWl81elJ0ZUNsMktNZ1VBN0FWTTdzeTdXNjd5SFQydUN6WWxTR2tHMmZ2VDhiZ1pncE1yT1h4MzVXT1A5THhHWEJLZU…
CMPX Jan 2028 1.500 call (CMPX280121C00001500) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE90MG1ySGJBLU0zRl9TTHJEcjVuQjRFWjVpZGxra05KZlhlWXJTNVJLRS13WlFrZTJBSHExSTZSR1lucnRLN3dwSHBLN1NzZGo0OFBrZnk4dERQOF9VOVY3bzd2dnVHSW1ZcGhVU0JR?oc=5" target="_blank">CMPX Jan 2028 1.500…
CMPX — Frequently Asked Questions
What is the current share price of Compass Therapeutics, Inc. (CMPX)?
As of 2026-10-23 16:27 PDT, Compass Therapeutics, Inc. (CMPX) trades at $0.76 on NasdaqCM. Its 52-week range is $0.76 to $6.69.
What is the market capitalisation of CMPX?
Compass Therapeutics, Inc. (CMPX) has a market capitalisation of $136.87M on NasdaqCM.
What is the P/E ratio of CMPX?
CMPX trades at a trailing price-to-earnings (P/E) ratio of -1.95. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.08.
What is the return on equity (ROE) of CMPX?
CMPX has a return on equity (ROE) of -56.66%. Its return on capital employed (ROCE) is -35.42%.
Is CMPX a good stock to buy?
This page provides a data-driven analysis of Compass Therapeutics, Inc. (CMPX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.